Objectives: The Current Opioid Misuse Measure (COMM) is a selfreport measure of risk for aberrant medication-related behavior among persons with chronic pain who are prescribed opioids for pain. It was developed to complement predictive screeners of opioid misuse potential and improve a clinician's ability to periodically assess a patient's risk for opioid misuse. The aim of this study was to cross-validate the COMM with a sample of chronic noncancer pain patients.
A lthough the use of opioids for chronic noncancer pain is increasing, prescription opioid abuse as a negative consequence of opioid availability is also on the rise. 1, 2 Opioids can be an effective treatment for chronic pain, yet providers are reluctant to prescribe opioids because of concerns over tolerance, dependence, and addiction. Some pain centers where opioids are prescribed are overwhelmed with problem patients, and many physicians prescribing pain medication have little training in addiction or in dealing with aberrant medication-related behavior. 3 Physicians are often faced with the difficult position of providing appropriate pain relief while minimizing the inappropriate use of pain medications 4 and, in surveys of primary care physicians, a third of responders indicated that they would not, under any circumstance, prescribe opioids to patients with chronic noncancer pain. 5, 6 It is important for the successful treatment of chronic, noncancer pain to be able to identify patients on opioid regimens currently exhibiting abuse behavior. 7, 8 Clinicians continuously identify the need for additional opioid risk management tools and training to objectively assess and monitor chronic pain patients being considered for opioid therapy.
The Current Opioid Misuse Measure (COMM) 9 was created to enhance the treatment of chronic pain patients and improve clinician comfort with opioid therapy. The COMM is different from measures that were created to identify patient characteristics that would likely lead to trouble with opioids (predicting misuse behaviors). Rather, the COMM helps to identify those patients prescribed opioids for pain who are currently misusing opioids. The aim of this study was to cross validate the COMM in a new population of pain patients and to confirm the usefulness of this self-assessment to gauge who is currently misusing opioids.
Concise definitions of terms are important to minimize confusion and help to clarify the objectives of this study. 10 For purposes of this investigation, substance misuse is defined as the use of any drug in a manner other than how it is indicated or prescribed. Substance abuse is defined as the use of any substance when such use is unlawful, or when such use is detrimental to the user or others. Prescription opioid addiction is a primary, chronic, neurobiologic disease that is characterized by behaviors that include one of more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. 11, 12 Aberrant drug-related behaviors are any behaviors that suggest the presence of substance abuse or addiction. Determining an individual's potential for aberrant drug behaviors and preventing misuse of prescription opioids is important in the evaluation and management of patients with chronic pain.
MATERIALS AND METHODS

Participants
Participants were recruited and followed for 5 months as part of a larger study intended to cross validate the predictive validity of another scale [Screener and Opioid Assessment for Patients with Pain (SOAPP-R)]. 13 The COMM cross-validation study began only during the follow up assessment, five months following their recruitment. This study's procedures were approved by the Human Subjects Committee of the various participating centers. Chronic noncancer pain patients were recruited from pain management centers in Boston, MA; Toledo, OH; Allentown, PA; Indianapolis, IN; and Lebanon, NH. Patients prescribed opioids for their pain were informed about the study and invited to participate. This study took place with the cooperation of 5 different pain centers in 5 different states. Patients were recruited consecutively and flyers were available for the study in all of the centers. An inclusion criterion for participation in the study was that the participants were taking prescription opioids at the time that they participated in the trial. All participants signed an informed consent form and were assured that the information obtained through their questionnaire responses and from the urine toxicology screens would remain confidential and would not be part of their clinic record. Participant patients were paid with a $50 gift certificate for completing the measures.
COMM 9
The COMM contains 17 items rated from 0="never" to 4="very often" ( Table 1 ). The COMM was developed to track patient status over time, so items included in the COMM can be used repeatedly and provide an estimate of the patient's "current" status. Thus, items capture a 30-day time period (ie, "in the past 30 d"), and only behaviors that could change from time to time were included (ie, historical items were excluded). The 17 items are summed to create a total score.
Brief Pain Inventory 14
The Brief Pain Inventory (BPI) is a well-known, selfreport, multidimensional pain questionnaire. The BPI provides information about pain history, intensity, and location as well as the degree to which the pain interferes with daily activities, mood, and influences enjoyment of life. Scales (rated from 1 to 10) indicate the intensity of pain at its worst, at its least, average pain, and pain "right now." Test-retest reliability for the BPI reveals correlations of 0.93 for worst pain, 0.78 for usual pain, and 0.59 for pain now. Research suggests the BPI has adequate validity and has been adopted in many countries for clinical pain assessment, epidemiological studies, and in studies of the effectiveness of pain treatment. Although originally developed to assess cancer pain, the BPI has been validated for use for patients with chronic noncancer pain. 15 Prescription Drug Use Questionnaire 16 Self-report of patient status at follow-up was obtained using the Prescription Drug Use Questionnaire (PDUQ). This 42-item structured interview is probably the most welldeveloped abuse-misuse assessment instrument for pain patients at this time. 17 The PDUQ is a 20-minute interview during which the patient is asked about his or her pain condition, opioid use patterns, social and family factors, family history of pain and substance abuse, and psychiatric history. In an initial test of the psychometric properties of the PDUQ, the standardized Cronbach a was 0.79, suggesting acceptable internal consistency. Compton and her colleagues suggested that participants who scored below 11 did not meet the criteria for a substance use disorder, whereas whose with a score of 11 or greater showed signs of a substance use disorder. For this study, we used scores greater than 11 on the PDUQ as a positive indicator for the Aberrant Drug Behavior Index (ADBI).
Prescription Opioid Therapy Questionnaire 18
Each patient's physician was asked to complete the Prescription Opioid Therapy Questionnaire (POTQ). This 11-item scale, adapted from the Physician Questionnaire of Aberrant Drug Behavior, 19 was completed by the treating clinician to assess the misuse of opioids. The items reflect the behaviors outlined by Chabal and colleagues 20 that were indicative of substance abuse. The participating patient's chart was made available to the treating physician to facilitate accurate recall of information. Providers answered yes or no to 11 questions indicative of misuse of opioids, including multiple unsanctioned dose escalations, episodes of lost or stolen prescriptions, frequent unscheduled visits to the pain center or emergency room, excessive phone calls, and inflexibility around treatment options. The POTQ has been found to be significantly correlated with the PDUQ and abnormal urine screens (P<0.01) as an external measure of its validity. 21 Patients' ratings of craving opioid medication has also been found to be significantly correlated with physicians ratings on the POTQ. 21 Patients who were positively rated on 2 or more of the items met the criteria for prescription opioid misuse, as indicated in previous investigations. 13, 22 Toxicology Screen Patients were requested to provide a urine sample during their follow-up visit and to inform staff of their current medications. Patients were informed that information from the toxicology screen would remain confidential and not be part of their medical record. Each patient was given a specimen cup and instructed to provide a urine sample (B30-75 mL of urine) without supervision in the clinic bathroom. The research assistant at each center collected and shipped the sample to a central Quest Diagnostics lab (www.questdiagnostics.com). The results of the urine toxicology were sent directly to the research team. The treating physician and the clinic did not have access to the results. The report included evidence of 6-MAM (heroin), codeine, dihydrocodeine, morphine, oxycodone, oxymorphone, hydrocodone, hydromorphone, meperidine, methadone, propoxyphene, buprenophine, fentanyl, tramadol, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, phencyclidine, and ethyl alcohol.
ADBI
Patients were classified as to whether they engaged in an aberrant medication-related behavior or not. Aberrant medication incorporates a variety of behaviors commonly believed to be associated with opioid medication misuse, abuse, and addiction. 10 As there is no gold standard for identifying which patients are and which are not abusing their prescription medications, 17 we classified patients into categories of aberrant medication-related behavior by triangulating 3 perspectives: self-report via structured interview, physician report, and urine toxicology results. The ADBI is based on positive scores on (1) the selfreported PDUQ, (2) the physician-reported POTQ, and (3) the urine toxicology results. A positive rating on the PDUQ is an accumulated score higher than 11. A positive rating on the POTQ is given to anyone who has 2 or more physicianrated aberrant behaviors. 13 A positive rating from the urine screens is given to anyone with evidence of having taken an illicit substance (eg, cocaine) or an additional opioid medication that was not prescribed. We chose not to count the omission of a prescribed opioid medication from the urine screen results as a positive rating because of multiple factors that can contribute to this result (eg, subject ran out the medication before the urine screen). We also did not classify urines that were rejected by the laboratory. Urine screen results were confirmed based on the chart review of prescription history and a comparison between self-report at the time of the urine screen and the toxicology report. Those with positive scores on the PDUQ were given a positive ADBI. If this score was negative, then positive scores on both the urine toxicology screen and on the POTQ (Z2) contributed to a positive ADBI. This allowed for triangulation of data to identify those patients who admitted to aberrant medication-related behavior and those who underreported aberrant behavior (eg, low PDUQ scores, but positive POTQ and abnormal urine screen results). For those patients who did not have results of urine toxicology screens, ADBI classification was based on the results of the PDUQ and POTQ.
We believe that self-report, when positive, is the most direct measure of a substance use disorder, as false positives (ie, patients reporting the presence of a substance use disorder when none is present) are presumably quite rare. Thus, those participants who met the criteria for a substance use disorder based on the interviewer-administered PDUQ>11 were given a positive score on the ADBI. If not, then we scored the ADBI as positive if there were positive urine screen results and 2 or more physician-rated aberrant behaviors (POTQ>1). We decided this after considerable discussion because urine screens can be problematic (eg, mistakes can be made with urine screen results based on variable drug metabolites and different cutoffs used in detecting a drug). We also know from experience that physician ratings of aberrant behavior can be unreliable. 7, 23 An analysis of past data found that those with the most problematic urine screen results (eg, tested positive for cocaine) also were positive on the PDUQ, which lent support for the reliability of this classification method. 21 
Procedures
The 17-item COMM was administered to a group of chronic pain patients from the participating pain centers. All procedures for the cross validation were identical to those used in the validation stage. 9 All the patients completed the PDUQ and BPI, and a urine sample for toxicology screening was collected. Chart reviews were conducted to confirm prescriptions.
Statistical Analyses
Data were analyzed with SPSS (Statistical Package for the Social Sciences; Chicago, IL) v.18.0. Comparisons of the original and cross-validation demographic and pain characteristic data were analyzed using t test comparisons for independent samples for percentages and means. In addition, coefficient alpha and receiver operating characteristic (ROC) curve analyses were conducted. Comparison of the original and cross-validation ROC curves was made using MedCalc software (v. 9.5.2).
RESULTS
As part of another cross-validation study, 24 302 chronic pain patients were recruited and followed for 5 months. At the 5-month follow-up, 226 individuals (75%) completed the 17-item COMM. Table 2 presents demographic and descriptive data on the cross-validation sample as well as the original COMM validation sample reported by Butler and colleagues. 9 As the analyses presented in Table 2 suggest, the 2 samples were not significantly different for age, race (percentage of white versus percentage of minority), or percent holding at least a high school education. Significant differences were observed for the gender makeup of the 2 samples, with the cross validation having 48.2% women which was significantly fewer than the 61.7% in the original COMM validation sample (t=2.8, df=450, P=0.005) and marital status, with 56.5% married in the cross-validation sample and only 43% married in the original sample (t=2.9, df=450, P=0.004). Characteristics of the 2 pain patient samples were not different on most measured variables, with the exception of rated amount of pain relief from medications, which was greater in the original validation sample and pain interference with general activity which was greater in the original validation sample. Patients recruited in the initial study came from 2 hospital-based pain management centers and a private pain management treatment center; inclusion criteria were identical in both the studies.
Although 4 out of 19 variables examined were statistically significantly different, the 2 samples appeared to be generally similar.
COMM scores for patients in the cross-validation sample averaged 8.96 (SD=7.0) and ranged between 0 and 44. Of the 226 patients, 216 were rated on the ADBI and were classified as either positive (34.2%) or negative for aberrant medication-related behaviors. Of those with positive ADBIs, 95.5% had a positive PDUQ. The remaining individuals were identified based on the POTQ and urine toxicology data. Ten participants could not be classified because of the missing data. No differences were found between the 10 participants with missing data and the 216 who were classified. The original validation of the COMM suggested a cutoff score of 9, which would be suggestive of aberrant medication-related behaviors. Using this cutoff, 41.6% of the participants had a positive COMM score, whereas 58.4% had a negative score (below 9).
Cross Validation of COMM Reliability
The cross validation revealed good replication of the reliability (internal consistency) statistics of the COMM. Internal consistency for the cross validation was also excellent with a coefficient a of 0.83. This value compares well with the coefficient a obtained in the original study (0.86) suggesting that COMM has stable reliability parameters.
Cross Validation of Validity
As in the original validation, the validity test evaluated the COMM in relation to patients' ADBI scores after 5 months. Repetition of the ROC analysis revealed an area under the curve (AUC) of 0.79 (standard error=0.031; 95% confidence interval, 0.73-0.85; P<0.001). Figure 1 presents the ROC curve and Table 3 presents the sensitivity and specificity cutoff estimates for the range of the COMM Prediction Scores gauged against the ADBI. As expected, there was some shrinkage observed in the AUC value when tested in an entirely new population, although the shrinkage was minimal. The original ROC curve analysis yielded an AUC of 0.81 (standard error=0.031; 95% confidence interval, 0.74-86; P<0.001). A test of independent ROC curves was not significant (z=0.456, NS).
DISCUSSION
The present study reports on an effort to cross-validate the COMM. The COMM is a self-report measure of current risk for aberrant medication-related behavior among persons with chronic pain. In an original validation study, 18 the COMM was found to be a reliable and valid measure. Cross validation of a scale on a new sample of respondents is a rigorous psychometric step that is necessary, since scale development efforts like the one used to create the COMM selected items based on their correlation with the target construct. Cross validation ensures that the psychometric coefficients observed during construction are not inordinately based on chance relationships to the target construct in the original sample. Results of the cross-validation effort reported here suggest that the psychometric parameters of the COMM are not based solely on unique characteristics of the initial validation sample. Although the COMM requires additional research, this study suggests that it may be a better screening tool than other measures (eg, the CAGE 25 that has no empirical base with a chronic pain population). At a minimum, the COMM can be used to alert the physician to potential risks and avert future problems. Patients' responses to the COMM questions access information not necessarily obtained during a follow-up evaluation, especially by a nonspecialist. Documentation of these responses might prove helpful in a medical/legal context by providing a basis upon which to decide whether to request more frequent office visits, pill counts, urine toxicology screens, or discontinuation of therapy. Patients taking opioids for pain identified with high COMM scores may also benefit from motivational counseling focused on managing thoughts, feelings, and behaviors (eg, coping with urges, making lifestyle changes, avoiding drug use triggers), and education about the appropriate use of opioids and avoiding relapse. 26 The COMM should be used only with chronic pain patients being prescribed opioid therapy. Broad-based administration of the COMM for all patients with chronic pain would not be appropriate. The COMM may help the provider determine the level of monitoring appropriate for a particular patient. It also has the potential to be used to help modify patient behavior in collaboration with behavioral health professionals to directly address problems identified on the COMM (eg, overusing of medication and borrowing medication from others) and to implement lower risk therapies. COMM scores are based on the willing and direct responses of patients. Although the COMM contains items for which the "correct" response may not be immediately transparent, patients determined to "look good" on the COMM will not find it difficult to do so. In our initial clinical work with similar self-report questionnaires (SOAPP v.1, and SOAPP-R), we found that many patients are truthful in their responses. Yet, it is critical for providers to consider the COMM results in the context of information from other sources, including history and physical examination, the clinical interview, discussions with family members, laboratory findings, and review of medical records.
The COMM was devised as a self-report measure to predict current aberrant medication-related behavior based on past behavior and/or cognition. The COMM has been designed and validated to pick up a variety of problematic behaviors that may increase risk of opioid misuse but which may have different causes (eg, mood disorders, general problems with prescription nonadherence, addiction) and thus may warrant different clinical responses. The intent of this scale is to document current behavior on a periodic basis to continue to justify chronic opioid therapy and to help detect ongoing difficulties. It is our belief that the SOAPP-R and COMM will work in tandem to help identify problems associated with the use of prescription opioids for pain.
It is important to emphasize the limitations of this study. First, this study was conducted in anesthesia-based pain centers and included a volunteer sample of patients. The urine samples were collected unobserved and not all patients gave a urine sample for a toxicology screening. This raises the potential for selection bias because of missing data. When urine samples were not collected, 2 other sources of patient status were used, but risk of selection bias remains. Continued efforts are needed to validate the COMM in other settings. Second, as with any study seeking consent, patients needed to agree to participate and some selected not to take part in this study. We recognize that the participants in this study represent only a subset of patients prescribed opioids for their pain, and differences were found between the participants in the original validation study and this crossvalidation study, although the differences in the AUC were minimal. Third, usefulness of the present measure in a primary care clinic with patients with shorter duration of pain particularly needs to be determined. Attempts were made to include minorities, but further information on the usefulness of the COMM among different ethnic groups and pain populations is needed. Bayes Theorem 27 postulates that the predictive value of diagnostic or laboratory tests is not constant but must change with the proportion of patients who actually have the target disorder among those who undergo the diagnostic evaluation. Thus, it is critical that the COMM not be used as a general screener in a primary care practice. It should be used instead only with chronic pain patients prescribed long-term opioid therapy, regardless of the setting. Also, use of the COMM repeatedly over a longer period of time has yet to be assessed. Finally, shrinkage of coefficients obtained during cross validation of the ROC analyses is acknowledged. Although such shrinkage is expected, the AUCs for the cross validation and original validation samples were quite close (2 points difference; 0.79 and 0.81, respectively), both AUCs were well within each other's 95% confidence intervals, and the AUCs were not significantly different. These results suggest a successful cross validation. Although the sensitivity of the COMM at a cutoff of 9 was acceptable and comparable to the original validation, specificity was lower than desired in the cross validation. In this context sensitivity of a screener may be most important, as it may be most critical to ensure identification of those who later evidence problems with their medications. Lower specificity means that some patients will be mislabeled as having problems managing their medications when they do not in fact have such problems. As any screening device has false positives and false negatives, it is up to the provider to determine the level of tolerance for these types of errors with which he or she is comfortable. 28 Finally, it should be noted that how to operationally define the target (ie, aberrant medication-related behavior) is not wellestablished. Such factors add noise to the data used to validate and cross-validate a scale like the COMM. Nevertheless, this cross-validation effort demonstrates that identification of patients having problems with their opioid medications is significantly better than chance. And, as noted above, the COMM score should always be considered in light of other clinical data before medication decisions are made.
CONCLUSIONS
Cross validation of the COMM yielded promising results. Although there was "shrinkage" in the values, which is expected when moving to a completely new sample of patients, the predictive validity as measured by the AUC remained highly significant. The COMM may offer clinicians a way to monitor misuse behaviors and to develop treatment strategies designed to minimize continued misuse. The COMM may serve as a useful tool for those providers who need to document their patients' continued compliance and appropriate use of opioids for pain. The results of this measure may have the added benefit of reducing physicians' concerns related to prescribing opioids and may keep patients more cognizant of their need to be responsible with these medications.
